Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 More than 1,500 substance abuse ... convene in Indianapolis Aug. 2-6 ... Mid-Year Training Institute . The week-long training, held at ... one of our nation,s biggest public health challenges – ... Institute is a one-of-a-kind intensive training opportunity, offering more ...
(Date:7/31/2015)... 2015 The Physician-Patient Alliance for Health ... 28, 2015, "Surviving Your Hospital Stay: Physician-Patient Alliance ... Safety." A sentence was omitted from ... "PPAHS is a member of the National Coalition ... information on the National Coalition to Promote Continuous Monitoring ...
(Date:7/31/2015)... , July 31, 2015  Xcelience, a ... that it has made a structured cash investment ... company specializing in milling, micronization and powder size ... help grow Powdersize,s business while simultaneously adding a ... Xcelience,s portfolio of capabilities. "As ...
Breaking Medicine Technology:Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... announced that the US Food and Drug Administration (FDA) ... submissions for review of the investigational drug vandetanib in ... (MTC). The FDA also granted priority review status for ... User Fee Act (PDUFA) action date of 7 January ...
... RIVER, N.Y., Sept. 22 Netsmart Technologies, ... and services for health and human services ... prescribing and medication management system for behavioral ... from Surescripts®. Surescripts operates the ...
Cached Medicine Technology:US and EU Regulatory Submissions for Vandetanib in Advanced Medullary Thyroid Cancer Accepted for Review 2Netsmart Technologies' InfoScriber™ e-Prescribing Service Receives Additional Surescripts® Certifications 2Netsmart Technologies' InfoScriber™ e-Prescribing Service Receives Additional Surescripts® Certifications 3Netsmart Technologies' InfoScriber™ e-Prescribing Service Receives Additional Surescripts® Certifications 4
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... announced an important workshop at its new True North Conference Center. The medical ... so that the Jacksonville community may be more aligned in the effort to ...
(Date:7/31/2015)... ... July 31, 2015 , ... M3 USA MDLinx.com, source of the Smartest Doc ... Exam Courses. , The additions of Gastroenterology, Pulmonology and Allergy/Immunology round out an ... preparing for the exam easy and painless. MDLinx offers thousands of board-exam style ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... of surgeons and cosmetic experts gathered to see if they could reach a consensus ... procedures, including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on ...
(Date:7/31/2015)... ... 2015 , ... Cosmetic Town has proven itself as the ... surgery procedures including, but not limited to, abdominoplasty, blepharoplasty, rhinoplasty and septoplasty. ... fillers. , Staying up to date with the latest cosmetic trends has ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Transfinder, a ... 2015. , Total sales were up 16 percent year-over-year for the first six months ... Antonio Civitella said he expected Transfinder to beat last year’s record-revenue mark of $10.4 ...
Breaking Medicine News(10 mins):Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Cosmetic Town: Now Providing Interactive And Vital Medical Knowledge 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2
... Translational Science Institute (CTSI) and Tufts University today announced ... from the National Institutes of Health. These new ... original Clinical and Translational Science Award (CTSA) grant, UL1 ... National Center for Research Resources. "Community Engagement ...
... , TUESDAY, Oct. 27 (HealthDay News) -- Researchers are reporting ... D2 can eliminate vitamin D deficiency, and twice-monthly doses can ... , The dosage -- 50,000 international units (IU) every ... to be toxic, according to the study published in the ...
... ... and severe sciatica causes widespread disability, and represents a significant unmet medical ... new approach for reducing nerve root inflammation. This off-label treatment method, invented ... including new data from randomized, placebo-controlled studies. , ...
... , ... Emdeon,s vast reach across the U.S. healthcare industry with Susan G. Komen,s mission to ... ... partnership with Susan G. Komen for the Cure®, the world,s largest breast cancer advocacy ...
... Oct. 27 Health Fitness Corporation (NYSE Amex: FIT ... management solutions, will conduct a conference call to discuss its ... The call is scheduled for 4:30 p.m. ET on Wednesday, ... (412) 858-4600 to access the conference call, or can listen ...
... Oct. 27 , Robert A. Douglas, 1st ... , RJR Focus: SHC Career Division national sales growth, ... 20 years of previous sales management experience and over 6 ... SHC he has been fundamental in the development and implementation ...
Cached Medicine News:Health News:Tufts CTSI and Tufts University receive 4 NIH supplemental grant awards 2Health News:Tufts CTSI and Tufts University receive 4 NIH supplemental grant awards 3Health News:Short-Term, High-Dose Vitamin D2 May Ease Deficiency 2Health News:Revolutionary New Treatment for Sciatica Advances in the Clinic 2Health News:Revolutionary New Treatment for Sciatica Advances in the Clinic 3Health News:Revolutionary New Treatment for Sciatica Advances in the Clinic 4Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 2Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 3Health News:Susan G. Komen for the Cure Partners with Healthcare IT Leader Emdeon for Innovative Breast Health Awareness Campaigns 4Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 2Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 3Health News:Senior Healthcare Consultants and RJR Insurance Services, Inc. Announce 4th Quarter 2009 and 1st Quarter 2010 Sales Management Promotions 4
Immersion Oil, 1,250 cs...
Immersion oil for microscopy...
... system is a compact, convenient and precise ... a significant improvement in life quality through ... condition. , , The CoaguChek XS system ... CoaguChek S system. It encompasses several innovative ...
The First Check Home Drug Test is the first over-the counter, FDA approved home drug test that provides immediate information about the possible use of prescription drugs....
Medicine Products: